Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
AstraZeneca
Medtronic
Johnson and Johnson
McKinsey

Last Updated: January 29, 2022

Volunteer for clinical trials for DEMADEX at ClinicalTrialExchange

DrugPatentWatch Database Preview

DEMADEX Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Demadex, and when can generic versions of Demadex launch?

Demadex is a drug marketed by Roche and Mylan Speciality Lp and is included in two NDAs.

The generic ingredient in DEMADEX is torsemide. There are sixteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the torsemide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Demadex

A generic version of DEMADEX was approved as torsemide by TEVA on May 14th, 2002.

  Try it Free

Summary for DEMADEX
Drug patent expirations by year for DEMADEX
Drug Prices for DEMADEX

See drug prices for DEMADEX

Recent Clinical Trials for DEMADEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
New York City Health and Hospitals CorporationPhase 4
Sarfez Pharmaceuticals, Inc.Phase 1
Roxane LaboratoriesN/A

See all DEMADEX clinical trials

Paragraph IV (Patent) Challenges for DEMADEX
Tradename Dosage Ingredient NDA Submissiondate
DEMADEX TABLET;ORAL torsemide 020136

US Patents and Regulatory Information for DEMADEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche DEMADEX torsemide INJECTABLE;INJECTION 020137-002 Aug 23, 1993 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Mylan Speciality Lp DEMADEX torsemide TABLET;ORAL 020136-002 Aug 23, 1993 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Roche DEMADEX torsemide INJECTABLE;INJECTION 020137-001 Aug 23, 1993 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DEMADEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Speciality Lp DEMADEX torsemide TABLET;ORAL 020136-002 Aug 23, 1993 ⤷  Try it Free ⤷  Try it Free
Mylan Speciality Lp DEMADEX torsemide TABLET;ORAL 020136-003 Aug 23, 1993 ⤷  Try it Free ⤷  Try it Free
Mylan Speciality Lp DEMADEX torsemide TABLET;ORAL 020136-002 Aug 23, 1993 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Mallinckrodt
Medtronic
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.